Download the Free Prime PubMed App to your smartphone or tablet.

Available for iPhone or iPad:

Unbound PubMed app for iOS iPhone iPadAlso Available:
Unbound PubMed app for Android

Available for Mac and Windows Desktops and laptops:

Unbound PubMed app for Windows
(fluticasone umeclidinium vilanterol)
50 results
  • Tiotropium/Olodaterol: A Review in COPD. [Journal Article]
    Drugs 2019; 79(9):997-1008Blair HA
  • Tiotropium/olodaterol (Stiolto® Respimat®; Spiolto® Respimat®) is an inhaled fixed-dose combination of the long-acting muscarinic antagonist tiotropium bromide (hereafter referred to as tiotropium) and the long-acting β2-adrenergic agonist olodaterol. It is available in several countries, including the USA, Japan, China and those of the EU, where it is indicated for the long-term maintenance trea…
  • [IMPACT study in COPD]. [Journal Article]
    Rev Med Liege 2019; 74(1):54-60Corhay JL
  • The role of the anti-inflammatory and bronchodilator triple therapy, including a long acting β2-agonist (LABA), a long-acting muscarinic antagonist (LAMA) and an inhaled corticosteroid (ICS), in the prevention of the exacerbations of chronic obstructive pulmonary disease (COPD) is still not clearly established, and requires comparison with dual therapy (LABA-CSI or LABA-LAMA). IMPACT is a phase 3…
  • Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. [Review]
    Int J Chron Obstruct Pulmon Dis 2018; 13:3971-3981Vanfleteren L, Fabbri LM, … Celli B
  • Recently, two "fixed triple" single-inhaler combinations of an inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA), and a long-acting muscarinic antagonist (LAMA) have become available for patients with COPD. This review presents the clinical evidence that led to the approval of these triple therapies, discusses the role of ICS in patients with COPD, and presents data on the relative ef…
New Search Next